Journal of Neurology

, Volume 242, Issue 2, pp 53–58 | Cite as

Measurement of immune markers in the serum and cerebrospinal fluid of multiple sclerosis patients during clinical remission

  • C. E. Shaw
  • P. R. Dunbar
  • H. A. Macaulay
  • T. J. Neale
Original Communication

Abstract

Magnetic resonance imaging of multiple sclerosis (MS) patients often shows active inflammatory lesions despite clinical remission. No immunological marker of disease activity has been identified in these patients. Concentrations of neopterin, interleukin-2 (IL-2), soluble interleukin-2 receptor (sIL-2R) and tumour necrosis factor-α (TNF-α) were measured in the serum and cerebrospinal fluid of 19 clinically-inactive MS patients and compared with those of 19 non-inflammatory controls. Cerebrosipnal fluid (CSF) neopterin concentrations were significantly higher in the MS group than in controls (mean 9.1 mM vs 3.4 nM,P<0.01) and 10 of 19 MS patients had levels above the control range. This finding provides evidence of ongoing T-cell-directed and interferon-gamma-mediated macrophage activation in the central nervous system. Analysis of IL-2, sIL-2R and TNF-a concentrations revealed no significant differences between MS patients and controls. We conclude that CSF neopterin concentration may correlate with disease activity in asymptomatic patients.

Key words

Multiple sclerosis Immune markers Neopterin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Adachi K, Kumamoto T, Araki S (1990) Elevated soluble interleukin-2 receptor levels in patients with active multiple sclerosis. Ann Neurol 28:687–691PubMedGoogle Scholar
  2. 2.
    Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wiotzerbin J (1988) Increased production of interferon gamma and tumour necrosis factor precedes clinical manifestations in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78:318–323PubMedGoogle Scholar
  3. 3.
    Beneviste EN, Sparacio SM, Bethea JR (1989) Tumor necrosis factor-α enhances interferon-γ- mediated class II antigen expression on astrocytes. J Neuroimmunol 25:209–219PubMedGoogle Scholar
  4. 4.
    Capra R, Mattioli F, Marciano N, Vignolo LA, Bettinzioli M, Airo P, Cattaneo R (1990) Significantly higher levels of soluble interleukin 2 in patients with relapsing-remitting multiple sclerosis compared with healthy subjects. Arch Neurol 47:254Google Scholar
  5. 5.
    Editorial (1989) Immunological treatment for multiple sclerosis. Lancet 1:699–671Google Scholar
  6. 6.
    Fesenmeier JT, Whitaker JT, Herman PK, Walker DP (1991) Cerebrospinal fluid levels of myelin protein-like material and soluble interleukin-2 receptor in multiple sclerosis. J Neuroimmunol 34:77–80PubMedGoogle Scholar
  7. 7.
    Franciotta DM, Grimaldi LME, Martino GV, Piccolo G, Bergamaschi R, Citterio A, Melzi d'Eril G (1989) Tumor necrosis factor in serum and cerebrospinal fluid of patients with multiple sclerosis. Ann Neurol 26:787–789PubMedGoogle Scholar
  8. 8.
    Fredrikson S, Enroth P, Link H (1987) Intrathecal production of neopterin in aseptic meningo-encephalitis and multiple sclerosis. Clin Exp Immunol 67:76–81PubMedGoogle Scholar
  9. 9.
    Fredrikson S, Link H, Enroth P (1987) CSF neopterin as a marker of disease activity in multiple sclerosis. Acta Neurol Scand 75:352–355PubMedGoogle Scholar
  10. 10.
    Freedman MS, Muth KL, Trotter JL, Yoshizawa CN, Antel JP (1992) Prospective serial analysis of interleukin-2 and soluble interleukin-2 receptor in relapsing-remitting multiple sclerosis. Neurology 42:1596–1601PubMedGoogle Scholar
  11. 11.
    Furukawa Y, Nishi K, Kondo T, Tanabe K, Mizuno Y (1992) Significance of CSF total neopterin and biopterin in inflammatory neurological diseases. J Neurol Sci 111:65–72PubMedGoogle Scholar
  12. 12.
    Gallo P, Piccino M, Pagni S, Tavolato B (1988) Interleukin-2 levels in serum and cerebrospinal fluid of multiple sclerosis patients. Ann Neurol 24:795–797PubMedGoogle Scholar
  13. 13.
    Gallo P, Piccinno MG, Krzalic L, Tavolato B (1989) Tumor necrosis factor-alpha and neurological diseases. Failure in detecting TNF-alpha in the cerebrospinal fluid from patients with multiple sclerosis, AIDS dementia complex and brain tumours. J Neuroimmunol 23:41–44PubMedGoogle Scholar
  14. 14.
    Gallo P, Piccinno MG, Pagni S, Argentiero V, Giometto B, Bozza F, Tavolato B (1989) Immune activation in multiple sclerosis: study of IL-2, sIL-2R, and gamma-IFN levels in serum and cerebrospinal fluid. J Neurol Sci 92:9–15PubMedGoogle Scholar
  15. 15.
    Gallo P, Piccinno MG, Tavalato B, Sidén A (1991) A longitudinal study on IL-2, sIL-2R, IL-4 and IFN-gamma in multiple sclerosis CSF and serum. J Neurol Sci 101:227–232PubMedGoogle Scholar
  16. 16.
    Greenburg SJ, Marcon L, Hurwitz BJ, Waldmann TA, Nelson DL (1988) Elevated levels of soluble interleukin-2 receptors in multiple sclerosis. N Enlg J Med 319:1019Google Scholar
  17. 17.
    Group TIMSS (1993) Interferon betalb is effective in relapsing- remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, doubleblind, placebo-controlled trial. Neurology 43:655–661Google Scholar
  18. 18.
    Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29:548–555PubMedGoogle Scholar
  19. 19.
    Hartung HP, Hughes RAC, Taylor WA, Heininger K, Reiners K, Toyka KV (1990) T cell activation in Guillain-Barre syndrome and in MS: elevated serum levels of soluble IL-2 receptors. Neurology 40:215–218PubMedGoogle Scholar
  20. 20.
    Hauser SL, Doolittle TH, Lincoln R, Brown RH, Dinarello CA (1990) Cytokine accumulations in CSF of multiple sclerosis patients: frequent detection of interleukin-1 and tumor necrosis factor but not interleukin-6. Neurology 40:1735–1739PubMedGoogle Scholar
  21. 21.
    Huber C, Batchelor JR, Fuchs D (1984) Immune response and associated production of neopterin. J Exp Med 160:310–316PubMedGoogle Scholar
  22. 22.
    Kittur SD, Kittur DS, Soncrant TT, Rapoport SI, Tourtelotte WW, Nagel JE, Adler WH (1990) Soluble interleukin-2 receptors in cerebrospinal fluid from individuals with various neurological disorders. Ann Neurol 28:168–173PubMedGoogle Scholar
  23. 23.
    Kurtzke IF (1961) On the evaluation of disability in multiple sclerosis. Neurology 11:686–694PubMedGoogle Scholar
  24. 24.
    Maimone D, Gregory S, Arnason BGW, Reder AT (1991) Cytokine levels in the cerebrospinal fluid and serum of patients with multiple sclerosis. J Neuroimmunal 32:67–74Google Scholar
  25. 25.
    McIntosh J, Murray-McIntosh R (1991) MacRIA, Wellington School of Medicine, P O Box 7343, Wellington, New ZealandGoogle Scholar
  26. 26.
    Miller DH, Rudge P, Johnson G, Kendall BE, Macmanus DG, Moseley IF, Barnes D, McDonald WI (1988) Serial gadolinium enhanced magnetic resonance imaging in mutilple sclerosis. Brain 111:927–939PubMedGoogle Scholar
  27. 27.
    Muller MM, Curtius HC, Herold M, Huber CH (1991) Neopterin in clinical practice. Clin Chim Acta 201:1–16PubMedGoogle Scholar
  28. 28.
    Noronha A, Toscas B, Jensen M (1992) Contrasting effects of alpha, beta, and gamma interferon on nonspecific suppressor functions in multiple sclerosis. Ann Neurol 31:103–106PubMedGoogle Scholar
  29. 29.
    Panitch H, Folus J, Johnson K (1987) Recombinant beta interferon inhibits gamma interferon production in multiple sclerosis (abstract). Ann Neurol 22:139Google Scholar
  30. 30.
    Panitch HS, Hirsch RL, Schindler J, Johnson KP (1987) Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of immune system. Neurology 37:1097–1103PubMedGoogle Scholar
  31. 31.
    Peter JB, Boctor FN, Tourtellotte WW (1991) Serum and CSF levels of IL-2, sIL-2R, TNF-alpha, and IL-1-beta: expected lack of clinical utility. Neurology 41:121–123PubMedGoogle Scholar
  32. 32.
    Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, Johnson KP, Sibley WA, Silberberg DH, Tiurtellotte WW (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227–231PubMedGoogle Scholar
  33. 33.
    Rubin LA, Nelson DL (1990) The soluble interleukin-2 receptor, biology, function, and clinical application. Ann Intern Med 113:619–627PubMedGoogle Scholar
  34. 34.
    Rudick RA, Barna BP (1990) Serum interleukin 2 and soluble interleukin 2 receptor in patients. Arch Neurol 47:254–255Google Scholar
  35. 35.
    Selmaj KW, Farooq M, Norton WT, Raine CS, Brosnam CF (1990) Proliferation of astrocytes in vitro in response to cytokines: a primary role for tumor necrosis factor. J Immunol 144:129–135PubMedGoogle Scholar
  36. 36.
    Sharief MK, Hentges R (1991) Association between tumor necrosis factor and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472PubMedGoogle Scholar
  37. 37.
    Sharief MK, Thompson EJ (1992) In vivo relationship of tumor necrosis factor-alpha to blood-brain barrier damage in patients with active multiple sclerosis. J Neuroimmunol 38:27–33PubMedGoogle Scholar
  38. 38.
    Sharief MK, Hentges R, Ciardi M, Thompson EJ (1993) In vivo relationship of interleukin-2 and soluble interleukin-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis. J Neurol 240:46–50PubMedGoogle Scholar
  39. 39.
    Smith KA (1984) Interleukin 2. Annu Rev Immunol 2:319–322PubMedGoogle Scholar
  40. 40.
    Tomioka R, Hamaguchi K, Ohno R, Hosokawa T, Kaneko A, Tsuji T, Kurihara K (1992) Elevated interleukin-2 levels in serum and cerebrospinal fluid of patients with relapsing-remitting multiple sclerosis. Ann NY Acad Sci 650:347–350PubMedGoogle Scholar
  41. 41.
    Traugott U, Lebon P (1989) Demonstration of alpha, beta and gamma interferon in active chronic multiple sclerosis lesions. Ann N Y Acad Sci 540:309–311Google Scholar
  42. 42.
    Trotter JL, Clifford DB, Anderson CB, Van Der Veen RC, Hicks BC, Banks G (1988) Elevated serum interleukin-2 levels in chronic progressive multiple sclerosis (letter). N Engl J Med 318:1206Google Scholar
  43. 43.
    Trotter JL, Collins KG, Van der Veen RC (1991) Serum cytokine levels in chronic progressive multiple sclerosis: interleukin-2 levels parallel tumor necrosis factor levels. J Neuroimmunol 33:29–36PubMedGoogle Scholar
  44. 44.
    Tsukada N, Miyagi M, Matsuda M, Yanagisawa N, Yone K (1991) Tumor necrosis factor and interleukin-1 in the CSF and sera of patients with multiple sclerosis. J Neurol Sci 102:230–234Google Scholar
  45. 45.
    Vass K, Heinenger K, Schafer B, Linington C, Lassmann H (1992) Interferon-gamma potentiates antibody-mediated demyelination in vivo. Ann Neurol 32:198–206PubMedGoogle Scholar
  46. 46.
    Willoughby EW, Grochowski E, Li DKB, Oger J, Kastrukoff LF, Paty DW (1989) Serial magnetic resonance scanning in multiple sclerosis: a second prospective study in relapsing patients. Ann Neurol 25:43–49PubMedGoogle Scholar

Copyright information

© Springer-Verlag 1995

Authors and Affiliations

  • C. E. Shaw
    • 1
  • P. R. Dunbar
    • 1
  • H. A. Macaulay
    • 1
  • T. J. Neale
    • 1
  1. 1.Department of MedicineWellington School of MedicineWellington SouthNew Zealand

Personalised recommendations